Profile: Teva Pharmaceutical Industries Ltd (TEVA.K)
10 Jul 2014
Teva Pharmaceutical Industries Limited (Teva), incorporated on February 13, 1944, is a global pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva’s active pharmaceutical ingredient (API) business provides vertical integration to Teva’s own pharmaceutical production. The Company’s global operations are conducted from North and Latin America to Europe and Asia. As December 31, 2010, it had direct operations in approximately 60 countries, including 40 finished dosage pharmaceutical manufacturing sites in 19 countries, 28 pharmaceutical research and development (R&D) centers and 21 API manufacturing sites. On October 14, 2011, it acquired Cephalon, Inc.
In August 2010, Teva completed the acquisition of Merckle ratiopharm Group (ratiopharm), which is a Germany-based generic pharmaceutical producer. On January 5, 2011, the Company acquired Laboratoire Theramex from Merck KGaA, which is a European-based women's health business. On January 26, 2011, Teva acquired Corporacion Infarmasa (Infarmasa). During the year ended December 31, 2010, it generated approximately 60% of its sales in North America, 25% in Europe and 15% in other regions (primarily Latin America, Israel, Russia and other Eastern European countries).
The Company manufactures and sells generic pharmaceutical products in a range of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants. It also focuses on sales of generic injectable products to hospitals, clinics and other institutional channels, primarily in the United States and Europe, including Latin America and Eastern Europe. Teva markets over 400 generic products in more than 1,300 dosage strengths and packaging sizes in the United States. During the year ended December 31, 2010, its total United States generic prescriptions included 611 million, and launched 18 generic versions. These include Mirapex, Trusopt, Cozaar, Hyzaar, Flomax, Activella, Valtrex, Subutex, Yaz, Differin, Arimidex, Effexor XR, Amerge, Catapres-TTS, Prozac Weekly, Diastat AcuDial, Prevacid SoluTab and Aricept ODT. Its sales organization consists of the Teva Generics group and the Teva Health Systems group.
The Company, through Teva Canada Limited, manufactures and markets generic prescription pharmaceuticals in Canada. Its generic product portfolio includes 290 generic products in 1,100 dosage forms and packaging sizes. During 2010, Teva launched Concerta ER, Actonel, Zyprex, Zydis, Proscar, Femara, Lipitor and Xatral. It has direct operations in 27 European Union member states, as well as in Norway and in Switzerland. The Company is a generic pharmaceutical company in 10 European countries, including the United Kingdom, Italy, Spain, the Netherlands, Portugal and Hungary, including Germany, France, Poland and the Czech Republic.
During 2010, Teva launched 24 generic versions in Europe. These generic versions include Hycamtin (topotecan HCl), Bipreterax (perindopril/ indapamide), Lercadip (lercanidipine), Co-Diovan (valsartan/hydrochlorothiazide), Rebetol (ribavirin), Cibacen (benazepril HCl), Cibadrex (benazepril HCl/HCTZ), Temodal (temozolomide), Viagra (sildenafil/ABC), Palladone (hydromorphone hydrochloride), Merrem (meropenem), Xalatan (latanoprost), Cipralex (escitalopram), Crestor (rosuvastatin calcium), Art (diacerein), Nexium (esomeprazole magnesium dihydrate), Trusopt (dorzolamide), Taxotere (docetaxel), Normix (rifaximin), Differine (adapalene), Aromasin (exemestane), Yasmin (ethinyl estradiol/drospirenone), Toplexil (oxomemazine) and erythropoietin.
Teva’s branded product offerings include its multiple sclerosis and neurology products, which include Copaxone for the treatment of multiple sclerosis, and Azilect for the treatment of Parkinson’s disease, as well as respiratory products, women’s health products and biopharmaceuticals, primarily biosimilars. Copaxone (glatiramer acetate injection (GA)) is used as a multiple sclerosis therapy in the United States and worldwide. Copaxone is also indicated for the treatment of patients who have experienced clinically isolated syndrome. The Company delivers a range of respiratory products for asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis.
The Company’s principal branded respiratory products in the United States include ProAir (albuterol HFA), which is a short-acting, beta-agonist for treatment of bronchial spasms linked to asthma or COPD and exercise-induced bronchospasm, and Qvar (beclomethasone diproprionate HFA), which is an inhaled corticosteroid for long-term control of chronic bronchial asthma. The Company’s main brands in the United Kingdom, France, Germany and the Netherlands include Qvar, and Airomir (salbutamol HFA), in metered dose inhalers (MDI), as well as in breath-actuated inhalers, such as Easi-Breathe and Autohaler, and salbutamol HFA MDI.
Teva’s women’s health unit manufactures and markets pharmaceutical products in the United States and Canada. Portfolio of products in North America includes Seasonique, LoSeasonique, Plan B One-Step OTC/Rx, ParaGard T380 A and Enjuvia. Seasonique, LoSeasonique are the Company’s extended regimen oral contraceptive products. The Company’s biosimilar products include Granulocyte Colony Stimulating Factor (GCSF), Eporatio (erythropoietin) and Tev-Tropin. GCSF stimulates the production of white blood cells and is primarily used to reduce the infections in oncology patients receiving chemotherapy. Eporatio (erythropoietin) stimulates the production of red blood cells and is used for the treatment of renal anemia or chemotherapy-induced anemia.
Teva Animal Health manufactures generic animal pharmaceuticals and markets dermatological and nutraceutical veterinary products in the United States. Teva Animal Health’s primary manufacturing, distribution, research and development, sales and marketing facilities are located in Missouri.
Teva Pharmaceutical Industries Ltd
5 Basel St.,
P.O. Box 3190
PETAH TIKVA 49131
Company Web Links
- UPDATE 2-EU fines 6 drug firms 428 mln euros for blocking cheaper drugs
- EU regulators fine Servier, Teva, others 428 mln euros
- Teva files petition with U.S. FDA against MS drug competitors
- UPDATE 1-U.S. allows Actavis Plc's purchase of Forest Labs with conditions
- EU to fine Servier, Teva for delaying generic drugs - sources